April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Cyclophosphamide for Ocular Inflammatory Diseases
Author Affiliations & Notes
  • S. Pujari
    Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts
  • J. H. Kempen
    Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania
  • C. W. Newcomb
    Dept. of Biostatistics & Epidemiology, Philadelphia, Pennsylvania
  • E. B. Suhler
    the Departments of Ophthalmology & Medicine, OHSU,Portland, Oregon
  • J. E. Thorne
    the Dept. of Ophthalmology, JHU, Baltimore, Maryland
  • D. A. Jabs
    Ophthalmology, Mount Sinai School of Medicine, New York,, New York
  • G. A. Levy-Clarke
    St. Luke’s Cataract and Laser Institute,, Tarpon Springs, Florida
  • R. B. Nussenblatt
    the Laboratory of Immunology, NEI, Bethesda, Maryland
  • J. T. Rosenbaum
    the Portland V.A. Medical Center, Portland, Oregon
  • C. S. Foster
    Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts
  • Footnotes
    Commercial Relationships  S. Pujari, None; J.H. Kempen, None; C.W. Newcomb, None; E.B. Suhler, None; J.E. Thorne, None; D.A. Jabs, None; G.A. Levy-Clarke, None; R.B. Nussenblatt, None; J.T. Rosenbaum, None; C.S. Foster, None.
  • Footnotes
    Support  National Eye Institute Grant EY014943 ,Research to Prevent Blindness, Mackall Foundation
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2020. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Pujari, J. H. Kempen, C. W. Newcomb, E. B. Suhler, J. E. Thorne, D. A. Jabs, G. A. Levy-Clarke, R. B. Nussenblatt, J. T. Rosenbaum, C. S. Foster; Cyclophosphamide for Ocular Inflammatory Diseases. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2020.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the effectiveness and safety of cyclophosphamide as an immunosuppressive treatment for non-infectious ocular inflammation.

Methods: : A retrospective cohort study of 251 patients with non-infectious ocular inflammation started on cyclophosphamide between 1979-2005 inclusive at five tertiary uveitis clinics was conducted by chart review. Dose of cyclophosphamide, response to therapy, corticosteroid-sparing effectiveness at every visit were noted. The frequency of discontinuation of cyclophosphamide and reasons for discontinuation also were noted. Proportions with success or failure at 6 and 12 months were estimated using Kaplan-Meier methods, and risk factors assessed using Cox regression.

Results: : Among the 251 patients (452 eyes) meeting inclusion criteria, 3.6%, 4%, 18.3%, 23.9%, 40.2%, and 10% had anterior uveitis, intermediate uveitis, posterior or panuveitis, scleritis, ocular mucous membrane pemphigoid, and other forms of ocular inflammation respectively. Among those active initially, control of inflammation ≥2 visits spanning ≥28 days was estimated to occur within ≤12 months in 65% overall. Among those on >10 mg of prednisone initially, sustained control of inflammation on a dose of ≤10 mg/day of prednisone within 12 months was 54%. Cyclophosphamide was discontinued in 193 patients (77%), most commonly due to side effects (81 patients, 32%) usually of a reversible nature, although life-threatening side effects were observed rarely. Sixty-one patients (32%) discontinued treatment because of disease remission.

Conclusions: : Our data suggest that cyclophosphamide as a single immunosuppressive agent was effective for controlling ocular inflammation in approximately two-thirds of patients within one year, and effective in meeting corticosteroid-sparing objectives in the majority of patients by one year. However, results were substantially better using less stringent success criteria. A minority of patients were able to discontinue therapy in disease remission. Side effects observed during follow-up at the clinics usually were reversible with dose adjustment, but require a high level of attention because life-threatening side effects occur occasionally.

Keywords: drug toxicity/drug effects • uveitis-clinical/animal model • clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.